ATLASPrelude Therapeutics (PRLD) earnings date: Nov 11, 2026
Prelude Therapeutics (PRLD) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 11, 2026, before the open. Analysts expect EPS of -$0.14.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on PRLD
| Last price | $3.89 (+0.1%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.4% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Prelude Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Prelude Therapeutics reports on Nov 11, 2026. One email the day before, with ATLAS’s read on Prelude Therapeutics. You can switch it off at any time.
Alert me before PRLD reportsFree to start. Creating an account takes under a minute.
PRLD earnings at a glance
| Next report (confirmed) | Wed, Nov 11, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.14 |
| Last report | Aug 11, 2026 · Beat |
| Beat rate (last 5 reports) | 3 of 5 (60%) |
| Average EPS surprise | +17.3% |
| Average move around a report | ±9.7% (last 5) |
| Sector | Healthcare · Biotechnology |
Prelude Therapeutics earnings history: last 5 reports
Prelude Therapeutics last reported on Aug 11, 2026: EPS of -$0.14 against an estimate of -$0.18 (+22.2% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 11, 2026 | -$0.18 | -$0.14 | +22.2% | Beat | +18.6% |
| Jun 18, 2026 | $1.59 | $1.58 | -0.6% | In line | -0.7% |
| May 29, 2026 | $0.74 | $0.92 | +24.3% | Beat | -2.8% |
| May 12, 2026 | -$0.27 | -$0.13 | +51.8% | Beat | -2.9% |
| Mar 10, 2026 | -$0.18 | -$0.20 | -11.1% | Miss | +23.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for PRLD
See the fair value, the probability range and the earnings history of Prelude Therapeutics on its ATLAS page.
Prelude Therapeutics (PRLD) stock analysisPlans from €3.99 a month.
Prelude Therapeutics earnings: frequently asked questions
When does Prelude Therapeutics (PRLD) report earnings?
Prelude Therapeutics is scheduled to report on Wednesday, November 11, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for PRLD?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.14 per share (USD). Estimates can change before the report.
How often does PRLD beat earnings estimates?
Of its last 5 reports with a recorded result, Prelude Therapeutics beat the EPS estimate 3 times; the average surprise was +17.3%. Past results do not predict the next one.
How much does PRLD move around earnings?
Over its last 5 reports the stock moved an average of 9.7% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Prelude Therapeutics beat earnings estimates last quarter?
Prelude Therapeutics last reported on Aug 11, 2026: EPS of -$0.14 against an estimate of -$0.18 (+22.2% surprise), a beat.
How much does PRLD usually move in a day?
On a normal trading day the ATLAS model puts PRLD’s one-day range at about ±4.4%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 11, 2026
Educational information, not investment advice. Disclaimer